ALSO NOTED: Takeda and Dey settle Alabama suit; Teva loses North American CEO

> Two pharma companies--Takeda Pharmaceuticals and Dey--agreed to pay a total of $7 million to the State of Alabama to settle claims that they fraudulently inflated their reported prices for prescription drugs. Report

> Teva Pharmaceutical Industries' North American CEO George Barrett has left the company to become vice chairman and healthcare supply chain chief of Cardinal Health. He'll be replaced by William Marth, president and CEO of Teva USA. Report

> Perrigo announced it would buy UK-based over-the-counter supplier Galpharm Healthcare for $86 million in cash. Report

> Novo Nordisk has tapped Alan Moses as its chief medical officer worldwide; previously, Moses was medical officer of the company's U.S. affiliate. Release

> BioAlliance Pharma got regulatory OK to sell its candidiasis treatment Loramyc in Denmark and Britain. Report

> A universal flu vaccine may be on the horizon. Report

> A new study appears to fully sever the alleged link between the mercury-containing thimerosal and autism. Report

> The paucity of NME approvals by the FDA last year--a miserly 16, one of the worst records in decades--is attracting worried comment from all angles in the drug development business. Report

And Finally... Think pharma could find a way to market canine companionship? It's proving to not only lower blood pressure, but even lower cholesterol and cut heart attack risk. Report 

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.